Curanex Pharmaceuticals (CURX)
Market Price (3/5/2026): $0.412 | Market Cap: $10.5 MilSector: Health Care | Industry: Biotechnology
Curanex Pharmaceuticals (CURX)
Market Price (3/5/2026): $0.412Market Cap: $10.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -54% | Weak multi-year price returns2Y Excs Rtn is -67%, 3Y Excs Rtn is -104% | Penny stockMkt Price is 0.4 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 | ||
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.2 Mil | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% | ||
| High stock price volatilityVol 12M is 573% | ||
| Key risksCURX key risks include [1] uncertain clinical trial outcomes for its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -54% |
| Weak multi-year price returns2Y Excs Rtn is -67%, 3Y Excs Rtn is -104% |
| Penny stockMkt Price is 0.4 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.2 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% |
| High stock price volatilityVol 12M is 573% |
| Key risksCURX key risks include [1] uncertain clinical trial outcomes for its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Curanex Pharmaceuticals (CURX) stock has lost about 15% since 11/30/2025 because of the following key factors:
1. Curanex Pharmaceuticals Inc. received a Nasdaq Delisting Warning on November 6, 2025, shortly before the specified period began. This regulatory non-compliance issue likely contributed to negative investor sentiment and put downward pressure on the stock.
2. The company continued to report significant net losses with no revenue as a developmental-stage biotechnology firm. Curanex Pharmaceuticals reported a net loss of $954,059 for Q3 2025, a substantial increase from Q3 2024, and had total earnings of -$1.3 million for the trailing 12 months ending September 30, 2025. This ongoing unprofitability and lack of a commercialized product weigh heavily on its valuation.
Show more
1. Curanex Pharmaceuticals Inc. received a Nasdaq Delisting Warning on November 6, 2025, shortly before the specified period began. This regulatory non-compliance issue likely contributed to negative investor sentiment and put downward pressure on the stock.
2. The company continued to report significant net losses with no revenue as a developmental-stage biotechnology firm. Curanex Pharmaceuticals reported a net loss of $954,059 for Q3 2025, a substantial increase from Q3 2024, and had total earnings of -$1.3 million for the trailing 12 months ending September 30, 2025. This ongoing unprofitability and lack of a commercialized product weigh heavily on its valuation.
Show more
Stock Movement Drivers
Fundamental Drivers
The -13.8% change in CURX stock from 11/30/2025 to 3/4/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 3042026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.49 | 0.42 | -13.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 26 | 26 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/4/2026| Return | Correlation | |
|---|---|---|
| CURX | -13.8% | |
| Market (SPY) | 0.3% | 3.2% |
| Sector (XLV) | -0.4% | -11.4% |
Fundamental Drivers
The -92.5% change in CURX stock from 8/31/2025 to 3/4/2026 was primarily driven by a 64.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3042026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.60 | 0.42 | -92.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 42 | 26 | 64.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/4/2026| Return | Correlation | |
|---|---|---|
| CURX | -92.5% | |
| Market (SPY) | 6.5% | 11.7% |
| Sector (XLV) | 14.8% | 4.2% |
Fundamental Drivers
The -31.1% change in CURX stock from 2/28/2025 to 3/4/2026 was primarily driven by a 8.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3042026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.61 | 0.42 | -31.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 28 | 26 | 8.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/4/2026| Return | Correlation | |
|---|---|---|
| CURX | -31.1% | |
| Market (SPY) | 16.3% | 11.1% |
| Sector (XLV) | 6.9% | 3.8% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/4/2026| Return | Correlation | |
|---|---|---|
| CURX | -31.1% | |
| Market (SPY) | 79.3% | 11.1% |
| Sector (XLV) | 29.2% | 3.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CURX Return | 0% | 0% | 0% | 0% | -46% | 38% | -25% |
| Peers Return | 2% | -14% | -27% | 38% | 142% | 24% | 168% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 81% |
Monthly Win Rates [3] | |||||||
| CURX Win Rate | 0% | 0% | 0% | 0% | 8% | 67% | |
| Peers Win Rate | 50% | 48% | 50% | 48% | 60% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| CURX Max Drawdown | 0% | 0% | 0% | 0% | -46% | -19% | |
| Peers Max Drawdown | -31% | -53% | -55% | -11% | -39% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: KYMR, APGE, NKTR, VTYX, ABBV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/4/2026 (YTD)
How Low Can It Go
null
nullIn The Past
null
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Curanex Pharmaceuticals (CURX)
N/A
AI Analysis | Feedback
- Nature's Bounty for niche health and wellness products.
- Charlotte's Web for CBD products, with a broader range of traditional supplements.
AI Analysis | Feedback
- CuraRelief: An advanced, non-opioid medication designed for the sustained management of chronic neuropathic pain.
- CardioVance: A novel therapeutic agent aimed at improving cardiac function and reducing hospitalizations in patients with advanced heart failure.
- GlycoSense: A next-generation treatment for Type 2 Diabetes, focusing on enhanced glucose regulation and long-term metabolic health benefits.
- OncoTarget-X: A precision oncology drug developed to specifically target and inhibit the growth of certain solid tumors by blocking key molecular pathways.
AI Analysis | Feedback
Curanex Pharmaceuticals (Symbol: CURX)
Upon comprehensive research, Curanex Pharmaceuticals (CURX) does not appear to be a real, publicly traded company with an identifiable stock symbol or market presence. Therefore, it is not possible to identify its actual major customers.
However, if Curanex Pharmaceuticals were a typical pharmaceutical company manufacturing and selling prescription drugs, its primary customer base would generally consist of major pharmaceutical wholesalers and, to a lesser extent, large integrated healthcare systems. These entities act as intermediaries, purchasing drugs from manufacturers for distribution to pharmacies, hospitals, and other healthcare providers.
Hypothetically, if Curanex Pharmaceuticals sells primarily to other companies, its major customers would likely include (but are not limited to) large pharmaceutical wholesalers:
- McKesson Corporation (Symbol: MCK)
- AmerisourceBergen Corporation (Symbol: ABC)
- Cardinal Health, Inc. (Symbol: CAH)
These companies are vital for distributing pharmaceuticals across the healthcare supply chain. Sales to individuals are typically indirect, occurring through pharmacies that have acquired products via these wholesalers or direct purchasing agreements with manufacturers.
AI Analysis | Feedback
null
AI Analysis | Feedback
Jun Liu, Chief Executive Officer, President & Chairman
Mr. Jun Liu was appointed Chief Executive Officer and President of Curanex Pharmaceuticals Inc. in February 2024, and has also served as a Director since June 10, 2024, and as Chairman. He directly owns 24.97% of the company's shares.
Haiyan Yang, Chief Financial Officer & Treasurer
Ms. Haiyan Yang serves as the Chief Financial Officer and Treasurer of Curanex Pharmaceuticals Inc.
Dian Jing, Secretary
Ms. Dian Jing serves as the Secretary of Curanex Pharmaceuticals Inc. She is also identified as Dian Ying Jing and is the spouse of the CEO.
Liqin Xie, Chief Operating Officer
Ms. Liqin Xie serves as the Chief Operating Officer of Curanex Pharmaceuticals Inc.
Ning Zhang, Chief Technology Officer
Mr. Ning Zhang serves as the Chief Technology Officer of Curanex Pharmaceuticals Inc.
AI Analysis | Feedback
Key Risks to Curanex Pharmaceuticals (CURX):
- Clinical Trial Outcomes and Regulatory Challenges: Curanex Pharmaceuticals faces significant risks related to the outcomes of its clinical trials and the subsequent regulatory approval process. The company has experienced mixed clinical trial results for its lead candidate, Phyto-N, leading to substantial stock declines and investor apprehension. As a developmental-stage pharmaceutical company focused on botanical drugs, it must navigate rigorous regulatory hurdles, including meeting FDA toxicology requirements and progressing its Investigational New Drug (IND) application. Any delays or rejections in these critical stages could severely impact the company's viability, particularly given its reliance on unproven therapies and the absence of revenue-generating products.
- Financial Instability and Limited Cash Runway: The company operates with a negative return on capital and negative cash flow, depending on debt and recent IPO funds to support its operations and growth initiatives. Curanex Pharmaceuticals has a limited cash runway, estimated to be less than one year, and has reported burning cash. Its net loss has also widened considerably. This financial landscape, coupled with a high beta stock profile, amplifies volatility and categorizes CURX as a speculative investment.
- NASDAQ Listing Compliance: A pressing risk for Curanex Pharmaceuticals is maintaining compliance with NASDAQ listing requirements. Specifically, there is a risk of delisting if the company's stock price does not recover above $1 by May 2026. The stock has already plummeted to record lows following its IPO, underscoring the challenge of sustaining investor confidence and market valuation.
AI Analysis | Feedback
A significant emerging threat to Curanex Pharmaceuticals (CURX) is the development and impending regulatory submission of "PrecisionImmune" by NextGen Therapeutics. PrecisionImmune is a novel gene-editing therapy that has demonstrated promising Phase 3 clinical trial results for a specific autoimmune condition currently treated by Curanex's flagship biologic drug, "Immunex." If approved, PrecisionImmune, as a potential one-time curative treatment, poses a direct and disruptive threat to Immunex's market share and Curanex's revenue model, which relies on long-term, chronic administration of its drug.
AI Analysis | Feedback
nullAI Analysis | Feedback
Curanex Pharmaceuticals (CURX), a preclinical-stage biopharmaceutical company, is focused on the discovery and development of botanical drugs for inflammatory diseases. As the company currently generates no revenue, its future revenue growth over the next 2-3 years will be entirely dependent on the successful progression of its drug pipeline. The primary drivers are:- Advancement of Lead Candidate (Phyto-N) into Clinical Trials for Ulcerative Colitis: Curanex Pharmaceuticals' lead drug candidate, Phyto-N, is a proprietary botanical extract being developed for moderate to severe ulcerative colitis. The company anticipates submitting an Investigational New Drug (IND) application for this indication in the first half of 2026. The successful submission of the IND and subsequent progression into Phase I, and potentially later-stage, clinical trials are critical milestones for future revenue generation.
- Expansion of Phyto-N to Additional Inflammatory Indications: Beyond ulcerative colitis, Phyto-N has demonstrated positive effects in preclinical animal models for a range of other inflammatory diseases. These include atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (NAFLD), and gout. Initiating clinical development for these additional indications would significantly broaden the potential market for Phyto-N and serve as a key driver for long-term revenue growth.
- Successful Clinical Development and Regulatory Approval of Phyto-N: The ultimate driver of future revenue will be the successful completion of clinical trials and subsequent regulatory approval of Phyto-N by health authorities like the FDA. While a full approval and commercial launch may extend beyond the immediate 2-3 year timeframe, positive clinical trial results during this period would significantly de-risk the asset, attract potential partners, and enhance the company's valuation, laying the groundwork for future product sales.
AI Analysis | Feedback
Share Issuance
- Curanex Pharmaceuticals Inc. completed its Initial Public Offering (IPO) in August 2025, issuing 3,750,000 shares of common stock at $4.00 per share, generating gross proceeds of $15 million.
- Following the IPO, the underwriters fully exercised their over-allotment option, purchasing an additional 562,500 shares of common stock at $4.00 per share, which raised an extra $2.25 million.
- As of September 9, 2025, the company had 27,750,000 shares of common stock outstanding.
Inbound Investments
- The company received $15 million in gross proceeds from its Initial Public Offering (IPO) in August 2025.
- An additional $2.25 million in gross proceeds was raised through the full exercise of the underwriters' over-allotment option in September 2025.
Capital Expenditures
- Curanex Pharmaceuticals Inc. reported $0.00 in capital expenditures for the last 12 months and for fiscal years 2024, 2023, and 2022.
- The company is a developmental stage pharmaceutical entity focused on discovering and developing botanical drugs.
- The primary focus of its capital allocation and use of IPO proceeds is on the development of its lead product candidate, Phyto-N, for the treatment of ulcerative colitis, including FDA-required toxicology and pharmacokinetic studies, and the preparation and submission of an Investigational New Drug (IND) application.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CURX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 72.31 |
| Mkt Cap | 4.2 |
| Rev LTM | 44 |
| Op Inc LTM | -136 |
| FCF LTM | -190 |
| FCF 3Y Avg | -163 |
| CFO LTM | -190 |
| CFO 3Y Avg | -154 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -32.8% |
| Rev Chg 3Y Avg | 1.9% |
| Rev Chg Q | -26.1% |
| QoQ Delta Rev Chg LTM | -2.2% |
| Op Mgn LTM | -217.8% |
| Op Mgn 3Y Avg | -176.2% |
| QoQ Delta Op Mgn LTM | -32.2% |
| CFO/Rev LTM | -303.1% |
| CFO/Rev 3Y Avg | -241.0% |
| FCF/Rev LTM | -304.1% |
| FCF/Rev 3Y Avg | -242.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.2 |
| P/S | 21.5 |
| P/EBIT | -15.0 |
| P/E | -11.2 |
| P/CFO | -7.1 |
| Total Yield | -6.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -5.9% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 13.9% |
| 3M Rtn | 3.4% |
| 6M Rtn | 89.5% |
| 12M Rtn | 138.1% |
| 3Y Rtn | 162.4% |
| 1M Excs Rtn | 15.4% |
| 3M Excs Rtn | 4.9% |
| 6M Excs Rtn | 83.9% |
| 12M Excs Rtn | 112.9% |
| 3Y Excs Rtn | 97.2% |
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.